A trial study conducted in participating centers in the Netherlands and Belgium concluded that ”the addition of HIPEC to interval cytoreductive surgery resulted in longer recurrence-free survival and overall survival than surgery alone” in patients with stage III epithelial ovarian cancer. 245 patients in this study were randomized between interval cytoreductive surgery alone and interval cytoreductive surgery with HIPEC (Hyperthermic Intraperitoneal Chemotherapy). Cytoreductive surgery is a surgical procedure to remove all visible tumors.The HIPEC procedure is designed to be used after Cytoreductive surgery in an attempt to kill any remaining cancer cells with a heated sterile solution–containing a chemotherapeutic. The study found that patients who underwent cytoreductive surgery with HIPEC had a median overall survival of 45.7 months.
To read more about this study, view the abstract on the The New England Journal of Medicine.